Hold On TG’s Program Stems From Existing – Not New – Concerns
‘Sub-par’ Disclosure Draws Analyst Finger Wagging
TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.
